CARDIFF ONCOLOGY, INC. (CRDF) Operating Margin
- Operating margin · 12 months: Value -8320.08%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -8320.08% | Operating income / revenue. Period ending 2026-06-30. $-42.27M ÷ $508.00K × 100 ≈ -8320.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -42.27M USD | Operating Income (Loss) |
| Revenue | 508.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 16.82M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-42.27M | $508.00K | (m) | (m) | $16.82M | -8320.08% |
| 2026-03-31 | $-47.43M | $525.00K | (m) | (m) | $16.34M | -9033.90% |
| 2025-12-31 | $-48.96M | $593.00K | (m) | (m) | $14.22M | -8256.32% |
| 2025-09-30 | $-53.70M | $501.00K | (m) | (m) | $14.24M | -10719.56% |
| 2025-06-30 | $-54.33M | $545.00K | (m) | (m) | $13.47M | -9969.17% |
| 2025-03-31 | $-52.10M | $587.00K | (m) | (m) | $13.37M | -8875.64% |
| 2024-12-31 | $-48.65M | $683.00K | (m) | (m) | $12.48M | -7123.13% |
| 2024-09-30 | $-46.41M | $688.00K | (m) | (m) | $12.20M | -6745.78% |
| 2024-06-30 | $-44.63M | $665.00K | (m) | (m) | $12.01M | -6711.28% |
| 2024-03-31 | $-44.29M | $610.00K | (m) | (m) | $13.09M | -7261.15% |
| 2023-12-31 | $-45.41M | $488.00K | (m) | (m) | $13.04M | -9305.74% |
| 2023-09-30 | $-44.47M | $460.00K | (m) | (m) | $13.40M | -9667.83% |
| 2023-06-30 | $-42.65M | $412.00K | (m) | (m) | $13.53M | -10350.73% |
| 2023-03-31 | $-40.88M | $395.00K | (m) | (m) | $12.32M | -10349.37% |
| 2022-12-31 | $-39.90M | $386.00K | (m) | $27.10M | $13.18M | -10337.31% |
| 2022-09-30 | $-40.04M | $391.00K | (m) | (m) | $13.94M | -10239.39% |
| 2022-06-30 | $-38.04M | $384.00K | (m) | (m) | $13.79M | -9906.51% |
| 2022-03-31 | $-34.49M | $361.00K | (m) | (m) | $13.54M | -9553.19% |
| 2021-12-31 | $-28.86M | $359.00K | (m) | $17.40M | $11.84M | -8037.60% |
| 2021-09-30 | $-25.83M | $344.99K | (m) | (m) | $11.42M | -7485.91% |
| 2021-06-30 | $-23.19M | $395.99K | (m) | (m) | $10.13M | -5856.38% |
| 2021-03-31 | $-20.40M | $369.99K | (m) | (m) | $8.97M | -5514.66% |
| 2020-12-31 | $-19.09M | $365.99K | (m) | $11.24M | $8.22M | -5214.82% |
| 2020-09-30 | $-16.88M | $340.81K | (m) | (m) | $6.32M | -4952.39% |
| 2020-06-30 | $-16.72M | $256.10K | (m) | (m) | $6.11M | -6530.01% |
| 2020-03-31 | $-16.84M | $250.31K | (m) | (m) | $5.87M | -6727.82% |
| 2019-12-31 | $-16.68M | $244.63K | (m) | (m) | $5.76M | -6817.79% |
| 2019-09-30 | $-16.49M | $230.07K | (m) | (m) | $5.93M | -7168.55% |
| 2019-06-30 | $-16.14M | $466.62K | (m) | (m) | $6.35M | -3459.04% |
| 2019-03-31 | $-16.36M | $440.15K | (m) | (m) | $6.98M | -3716.97% |
| 2018-12-31 | $-17.05M | $378.32K | (m) | (m) | $8.01M | -4507.61% |
| 2018-09-30 | $-16.73M | $485.34K | (m) | (m) | (m) | -3447.96% |
| 2018-06-30 | $-18.68M | $520.30K | (m) | (m) | (m) | -3589.54% |
| 2018-03-31 | $-20.13M | $510.50K | (m) | (m) | (m) | -3942.23% |
| 2017-12-31 | $-25.60M | $505.40K | (m) | (m) | (m) | -5064.42% |
| 2017-09-30 | $-31.59M | $388.45K | (m) | (m) | (m) | -8133.29% |
| 2017-06-30 | $-35.72M | $354.24K | (m) | (m) | (m) | -10083.88% |
| 2017-03-31 | $-39.81M | $355.62K | (m) | (m) | (m) | -11195.14% |
| 2016-12-31 | $-40.15M | $381.07K | (m) | (m) | (m) | -10534.91% |
| 2016-09-30 | $-37.75M | $392.17K | (m) | (m) | (m) | -9625.32% |
| 2016-06-30 | $-34.23M | $360.38K | (m) | (m) | (m) | -9498.97% |
| 2016-03-31 | $-30.88M | $306.33K | (m) | (m) | (m) | -10082.18% |
| 2015-12-31 | $-25.27M | $312.81K | (m) | (m) | (m) | -8079.50% |
| 2015-09-30 | $-22.39M | $290.04K | (m) | (m) | (m) | -7720.70% |
| 2015-06-30 | $-19.92M | $289.91K | (m) | (m) | (m) | -6872.37% |
| 2015-03-31 | $-16.53M | $296.19K | (m) | (m) | (m) | -5581.89% |
| 2014-12-31 | $-14.95M | $280.18K | (m) | (m) | (m) | -5334.17% |
| 2014-09-30 | $-13.29M | $271.15K | (m) | (m) | (m) | -4901.55% |
| 2014-06-30 | $-12.43M | $257.70K | (m) | (m) | (m) | -4822.52% |
| 2014-03-31 | $-11.56M | $251.08K | (m) | (m) | (m) | -4604.32% |
| 2013-12-31 | $-10.69M | $259.25K | (m) | (m) | $7.00M | -4123.71% |
| 2013-09-30 | $-9.28M | $375.13K | (m) | (m) | (m) | -2472.76% |
| 2013-06-30 | $-7.24M | $542.87K | (m) | (m) | (m) | -1333.16% |
| 2013-03-31 | $-6.11M | $535.37K | (m) | (m) | (m) | -1141.03% |
| 2012-12-31 | $-4.85M | $450.40K | (m) | (m) | (m) | -1076.62% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-2.98M | $257.70K | (m) | (m) | (m) | -1155.16% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |